Table 7 Correlation between disease characteristics and PET-based therapeutic response in the study population
Objective response by PERCIST | Test value* | P value | Sig. | ||||
|---|---|---|---|---|---|---|---|
CMR | PMR | SMD | PMD | ||||
No. = 18 | No. = 9 | No. = 2 | No. = 4 | ||||
Pathology | |||||||
NHL | 10 (55.6%) | 1 (11.1%) | 1 (50.0%) | 3 (75.0%) | 7.894 | 0.246 | NS |
HL | 7 (38.9%) | 8 (88.9%) | 1 (50.0%) | 1 (25.0%) | |||
GALT | 1 (5.6%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |||
Location | |||||||
NA | 3 (16.7%) | 0 (0.0%) | 0 (0.0%) | 1 (25.0%) | 3.900 | 0.690 | NS |
Supra | 7 (38.9%) | 6 (66.7%) | 1 (50.0%) | 1 (25.0%) | |||
Supra & infra | 8 (44.4%) | 3 (33.3%) | 1 (50.0%) | 2 (50.0%) | |||
Stage | |||||||
I | 1 (5.6%) | 1 (11.1%) | 0 (0.0%) | 0 (0.0%) | 14.506 | 0.696 | NS |
IE | 1 (5.6%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |||
II | 5 (27.8%) | 5 (55.6%) | 1 (50.0%) | 0 (0.0%) | |||
IIE | 1 (5.6%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |||
III | 2 (11.1%) | 1 (11.1%) | 0 (0.0%) | 2 (50.0%) | |||
IIIS | 5 (27.8%) | 1 (11.1%) | 1 (50.0%) | 0 (0.0%) | |||
IV | 3 (16.7%) | 1 (11.1%) | 0 (0.0%) | 2 (50.0%) | |||
New lesion | |||||||
Absent | 18 (100.0%) | 9 (100.0%) | 2 (100.0%) | 0 (0.0%) | 33.00 | 0.000 | HS |
Present | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 4 (100.0%) | |||